Atlas Trials

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Clinical trial NCT02980341 · COMPLETED

Trial details

NCT number
NCT02980341
Sponsor
Daiichi Sankyo Co., Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2016-11-28
Primary completion
2021-08-16
Enrollment
182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.